Hilton Introduces Hilton EventReady with CleanStay, Setting New Standards for Event Cleanliness and Customer Service
13.7.2020 07:01:00 EEST | Business Wire | Press release
For more than 100 years, Hilton hotels around the world have set the stage for the world’s most coveted and important meetings, events and entertainment gatherings – from star-laden award shows and movie sets to energetic political conventions, global conferences and wow-worthy weddings. Today, that tradition continues – even at a safe distance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200712005004/en/
Hilton Introduces Hilton EventReady with CleanStay, Setting New Standards for Event Cleanliness and Customer Service. (Photo: Business Wire)
To address safe group travel practices and evolve today’s event experience, Hilton today announced a global, industry-leading cleanliness and customer service program specific to meetings and events. Hilton EventReady with CleanStay is the next phase of the company’s recently launched Hilton CleanStay and was shaped by extensive research and feedback.
“At Hilton, we’ve always believed in the power of in-person connections and take pride in the exceptional experiences our teams create in partnership with event professionals,” said Chris Nassetta, President and CEO, Hilton. “In today’s new normal, we know that people planning and attending events of any size are focused on their health and safety. Hilton EventReady delivers innovative solutions for the entire event experience – from flexibility in planning and physical distancing protocols to transparency in cleanliness policies and inspiring catering options.”
The key tenets of the Hilton EventReady with CleanStay program include:
- Cleanliness Protocols: The program expands on the elevated sanitation standards of the recently-announced Hilton CleanStay program, addressing every touch point of the meeting experience. This includes room seals for guest and meeting rooms, sanitizing stations in public areas and meeting spaces and EventReady Room Checklist.
-
Book-to-Billing Flexibility: Understanding the importance of flexibility, Hilton Teams will work hand-in-hand with customers to align on shared objectives, providing:
- Flexible pricing, space options and contract terms;
- Responsive offers to meet the needs of customers, like simplified agreements for small meetings;
- Hilton EventReady Playbook, which delivers expert guidance and curated resources for solutions, such as Hybrid Meetings that seamlessly combine on-site attendees with those in remote locations, Room Sets and Creative Networking.
-
Safe and Socially Responsible Solutions: To responsibly host meetings and events, Hilton Team Members will partner with their clients to achieve the meeting’s objectives while addressing both health and environmental concerns.
This includes presenting creative physical distancing meeting sets and meal service, developing inspiring food & beverage options and sharing environmental impact solutions measured by LightStay, Hilton’s award-winning corporate responsibility measurement platform.
Each meeting and event experience is backed by Hilton hospitality from dedicated Team Members who aim to overdeliver on client expectations from both the event professional and the attendees.
For more information on Hilton EventReady with CleanStay visit www.meetings.hilton.com/eventready.
###
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,100 properties with more than 977,000 rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton welcomed more than 3 billion guests in its 100-year history, earned a top spot on the 2019 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. Through the award-winning guest loyalty program Hilton Honors, more than 106 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including digital check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook, Twitter, LinkedIn, Instagram and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200712005004/en/
Contact information
Colleen Hart
Director, Global
Brand Communications
+1 703 883 6616
Colleen.Hart@Hilton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
